EXACT Sciences Co. (NASDAQ:EXAS) has been assigned an average recommendation of “Buy” from the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $110.90.
A number of equities analysts have commented on the company. BidaskClub cut Ames National from a “hold” rating to a “sell” rating in a research note on Wednesday. Canaccord Genuity upped their price target on Ideagen from GBX 170 ($2.22) to GBX 180 ($2.35) and gave the company a “buy” rating in a report on Wednesday. Craig Hallum upped their price objective on 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. BTIG Research upped their price objective on Apple to $234.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Monday, July 8th.
NASDAQ:EXAS traded up $1.16 on Friday, reaching $117.50. 30,357 shares of the stock traded hands, compared to its average volume of 1,134,850. The stock has a market capitalization of $14.99 billion, a price-to-earnings ratio of -86.07 and a beta of 1.64. The firm has a 50 day moving average of $112.44. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13. EXACT Sciences has a 1-year low of $47.78 and a 1-year high of $121.98.
Several institutional investors have recently made changes to their positions in EXAS. Grandview Asset Management LLC purchased a new stake in EXACT Sciences during the 2nd quarter worth approximately $224,000. Oakbrook Investments LLC boosted its holdings in shares of EXACT Sciences by 12.1% during the 2nd quarter. Oakbrook Investments LLC now owns 3,475 shares of the medical research company’s stock worth $410,000 after purchasing an additional 375 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $4,840,000. NEXT Financial Group Inc acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $50,000. Finally, IFM Investors Pty Ltd acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $961,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Featured Story: What is a bull market?
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.